Neil Kumar sold $6.0M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $75.54, traded Jan 8, 2026, filed Jan 12, 2026.
Score components
- +25RoleCEO
- +25Trade size$6.0M at market
- +5Share of holdings soldSold 11% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.6%, 3m +1.3%, 6m +8.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000026, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -11,515 | $73.64 | $848k | 744,171 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,085 | $74.38 | $601k | 736,086 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -400 | $75.16 | $30k | 735,686 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -11,565 | $73.65 | $852k | 4,546,882 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,135 | $74.38 | $605k | 4,538,747 | Jan 12, 2026 |
| Jan 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -300 | $75.20 | $23k | 4,538,447 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -2,151 | $75.75 | $163k | 733,535 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -6,955 | $76.72 | $534k | 726,580 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -10,519 | $77.61 | $816k | 716,061 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -375 | $78.19 | $29k | 715,686 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -1,401 | $75.61 | $106k | 4,537,046 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -6,067 | $76.53 | $464k | 4,530,979 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -10,677 | $77.46 | $827k | 4,520,302 | Jan 12, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -1,855 | $78.10 | $145k | 4,518,447 | Jan 12, 2026 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 35Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.7M 44,980 shares | -16% | |
| 6Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $160k 2,000 shares | -2% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $13M 148,589 shares | -95% | |
| 23Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $1.4M 17,167 shares | -43% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.